Provided by Tiger Fintech (Singapore) Pte. Ltd.

Passage Bio, Inc.

0.3802
-0.0201-5.02%
Post-market: 0.38020.00000.00%19:33 EDT
Volume:253.14K
Turnover:99.39K
Market Cap:23.63M
PE:-0.37
High:0.4081
Open:0.3932
Low:0.3729
Close:0.4003
Loading ...

Optimistic Buy Rating for Passage Bio’s PBFT02: Promising Efficacy and Managed Safety Concerns

TIPRANKS
·
28 Jun

Major Shareholder Orbimed Advisors Sells Huge Chunk of Passage Bio Stock!

TIPRANKS
·
27 Jun

OrbiMed Advisors LLC Reports Disposal of Common Shares of Passage Bio Inc

Reuters
·
27 Jun

Passage Bio Is Maintained at Buy by Chardan Capital

Dow Jones
·
24 Jun

Passage Bio’s Promising Clinical Trial Results and Strategic Adjustments Justify Buy Rating

TIPRANKS
·
24 Jun

Passage Bio (PASG) Receives a Buy from Chardan Capital

TIPRANKS
·
24 Jun

Passage Bio Releases Promising Interim Data for PBFT02

TIPRANKS
·
24 Jun

BRIEF-Passage Bio Reports Updated Interim Data From Uplift-D Study

Reuters
·
23 Jun

Passage Bio Announces Updated Interim Data and Program Advancements for PBFT02 in Frontotemporal Dementia Trial

Reuters
·
23 Jun

Passage Bio Inc - Dose 1 Pbft02 Shows Durable Increase in Csf Pgrn Levels

THOMSON REUTERS
·
23 Jun

Passage Bio Inc -Remain on Track to Seek Regulatory Feedback on Ftd-Grn Pivotal Trial Design in 1H 2026

THOMSON REUTERS
·
23 Jun

Passage Bio Reports Updated Interim Data From Uplift-D Study and Provides Program Update

THOMSON REUTERS
·
23 Jun

Passage Bio Adopts Key Proposals at Annual Meeting

TIPRANKS
·
31 May

Passage Bio Inc. Conducted Annual Stockholders Meeting

Reuters
·
31 May

Chardan Capital Reaffirms Their Buy Rating on Passage Bio (PASG)

TIPRANKS
·
15 May

Wedbush Remains a Buy on Passage Bio (PASG)

TIPRANKS
·
13 May

Wedbush Adjusts Price Target on Passage Bio to $3 From $4, Maintains Outperform Rating

MT Newswires Live
·
13 May

Passage Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

BRIEF-Passage Bio Q1 Income From Operations USD -16.459 Million

Reuters
·
13 May

Passage Bio Q1 EPS $(0.25) Misses $(0.23) Estimate

Benzinga
·
13 May